Antibody-Based Therapies for Colorectal Cancer

Antibody-Based Therapies for Colorectal Cancer Ki Young Chung, Leonard B. Saltz Oncologist 2005; 10: 701-709 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gastrointestinal cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Select the appropriate clinical use of cetuximab and bevacizumab in the treatment of metastatic colorectal cancer based on the currently available clinical trials' data and known toxicities of each agent. Discuss the controversy over EGFR testing in colorectal cancer patients and the lack of predictive value of EGFR expression by IHC. List the relevant clinical questions regarding the use of targeted agents in colorectal cancer that remain to be addressed by clinical trials. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2005 Most Recent Review: Oct. 25, 2005* Most Recent Update: Oct. 25, 2005 Date Credit Expires: Oct. 25, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.